So

Prescription products · Product label record

Sodium Sulfacetamide, Sulfur drug information

SODIUM SULFACETAMIDE 8% SULFUR 4%
Aspen Medical LLC · TOPICAL

Product NDC: 87026-203

Join the community
CommunityExperiencesReviewsDrug database
Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameSODIUM SULFACETAMIDE 8% SULFUR 4%
Labeler / manufacturerAspen Medical LLC
RouteTOPICAL
Drug classDrug class not supplied in source label
Product NDC87026-203
Label effective date2026-02-21

Official product label reference

Sodium Sulfacetamide, Sulfur — Aspen Medical LLC

This page contains 18 source sections for SODIUM SULFACETAMIDE 8% SULFUR 4%, topical route. Label set 4ba94e96-b107-77fe-e063-6394a90aa980, version 1.

Retrieved 2026-10-02 · openFDA dataset updated 2026-10-02 · Check the current DailyMed label

Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.

Uses described in the label

Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
Dosage and administration — label text
Apply Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension sooner or using less often.
Contraindications
This product is contraindicated for use by persons with known or suspected hypersensitivity to sulfonamides, sulfur or any other component of this preparation. This product is not to be used by patients with kidney disease.
Warnings
Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
Adverse reactions
Although rare, sodium sulfacetamide may cause local irritation. Call your doctor for medical advice about side effects.
Unclassified section
Rx Only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Keep out of reach of children. Keep container tightly closed. Keep away from eyes. Shake well before use. In case of accidental ingestion contact a Poison Control Center immediately. You may report side effects by calling the FDA at 1-800-FDA-1088 This bottle is not filled to the top but does contain 16 oz of product as identified on the front panel of the bottle. USA Manufactured For: Aspen Medical LLC 8 The Green Ste. B Dover, DE 19901 Rev. 10/25
Inactive ingredient
Aloe vera leaf extract, butylated hydroxytoluene, cetyl alcohol, citric acid, cocamidopropyl betaine, disodium EDTA, glycerin, glyceryl stearate SE, green tea extract, PEG-100 stearate, phenoxyethanol, purified water, sodium laureth sulfate, sodium thiosulfate, stearyl alcohol, triacetin, xanthan gum.
User safety warnings
CAUTION In case of itching or redness discontinue the use.
Storage and handling
Store at 20℃ to 25C ( 68°F to 77°F ), excursions permitted between 15C and 30C (between 59°F and 86°F ). Brief exposure to temperatures up to 40C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25C (77°F) however, such exposure should be minimized. Protect from freezing. In case of accidental ingestion contact a Poison Control Center immediately. Keep container tightly closed. You may report side effects by calling the FDA at 1-800-FDA-1088
Product description
Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl)sulfonyl]-acetamide monosodium salt, monohydrate. The structural formula is: Structure
Clinical pharmacology
The most widely accepted mechanism of action of sulfonamides is the woods-fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is not known, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.
Precautions
GENERAL If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility. INFORMATION FOR PATIENTS Avoid contact with eyes, eyelids, lips and mucous membranes, If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician. CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Long-term studies in animals have not been performed to evaluate carcinogenic potential. PREGNANCY Category C Animal reproduction studies have not been conducted with Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. It is not known whether Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension should be given to a pregnant woman only if clearly needed. NURSING MOTHERS It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is administered to a nursing woman. PEDIATRIC USE Safety and effectiveness in children under the age of 12 have not been established.
Information for patients
INFORMATION FOR PATIENTS Avoid contact with eyes, eyelids, lips and mucous membranes, If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.
Carcinogenesis and mutagenesis and impairment of fertility
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Pregnancy
PREGNANCY Category C Animal reproduction studies have not been conducted with Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. It is not known whether Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension should be given to a pregnant woman only if clearly needed.
Breastfeeding
NURSING MOTHERS It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is administered to a nursing woman.
Children and adolescents
PEDIATRIC USE Safety and effectiveness in children under the age of 12 have not been established.
Supply and packaging
Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is available in 16 fl oz (473 mL) bottles NDC 87026-203-16

Official sources and product identifiers

Substances listed: SULFACETAMIDE SODIUM, SULFUR

RxNorm identifiers: 1010234

Package NDC codes

87026-203-16

Further research and background

These are external searches for related information. Research, encyclopedia and news articles have not been imported into this product record.

Coverage and corrections

The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.

Source retrieved 2026-10-02. Read the source policy.